Active Not Recruiting PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT05148871

Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

A Phase 2b Study to Assess the Effect of Dose Interval on the Effectiveness of a Protein-based Covid-19 Vaccine (Spikogen® Vaccine)

Sponsor: Australian Respiratory and Sleep Medicine Institute

Conditions COVID-19

Interventions Spikogen/Covax-19

Updated 7 times since 2022 Last updated: Aug 6, 2024 Started: Mar 1, 2022 Primary completion: Feb 23, 2023 Completion: Oct 6, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on COVID-19, this trial is ongoing. The trial is conducted by Australian Respiratory and Sleep Medicine Institute and has accumulated 7 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2_PHASE3
Apr 2023 — May 2024 [monthly]

Active Not Recruiting PHASE2_PHASE3
Jun 2022 — Apr 2023 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Apr 2022 — Jun 2022 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting
Jan 2022 — Apr 2022 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Australian Respiratory and Sleep Medicine Institute
Cinnagen
Vaxine Pty Ltd

Data source: Vaxine Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia